ArticleInternational journal of clinical and experimental pathology2025
ROR1 expression in ovarian cancer patients and its association with chemotherapy response and prognosis.
Article in International journal of clinical and experimental pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Quantum Reactivity-Guided Optimization of ATP-Competitive Ligands through Multiscale Simulation.ACS physical chemistry Au · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the expression of receptor tyrosine kinase-like orphan receptor 1 (ROR1) in ovarian cancer tissues and its correlation with clinicopathologic features, chemotherapy sensitivity, and prognosis in patients with ovarian cancer.
methodsParaffin tissue blocks were collected from 227 ovarian cancer patients, and immunohistochemical (IHC) staining was performed to analyze the expression of ROR1. The associations between ROR1 expression and clinicopathologic features, treatment response, and prognosis were evaluated.
resultsROR1 expression and tumor load: higher expression of ROR1 was associated with a heavier tumor load in ovarian cancer patients. ROR1 and chemotherapy: the expression of ROR1 was significantly higher in patients who underwent interval debulking surgery (IDS) compared to primary debulking surgery (PDS) and subsequent chemotherapy (SSC). This suggests that chemotherapy may promote increased ROR1 expression in tumor tissues. Additionally, a trend of higher ROR1 expression was observed in platinum-sensitive patients. Nuclear expression in clear cell ovarian cancer: positive nuclear expression of ROR1 was unexpectedly detected in clear cell ovarian cancer, suggesting a link between ROR1 nuclear translocation and poor prognosis.
conclusionROR1 expression may be related to treatment strategy and history of platinum-based chemotherapy in ovarian cancer patients. Targeting ROR1 could represent a promising therapeutic strategy for the treatment of ovarian cancer. Further studies are needed to elucidate the role of ROR1 nuclear translocation in prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.